Drug intelligence / Profile preview

MG2512

Development stage: Phase 1
Lead developer: Maijin Biomedical Technology
Administration: Intravenous

Overview

MG2512 is an investigational therapeutic being developed by Shanghai Mabgen Biopharmaceutical Technology for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, where it is being evaluated for safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced malignancies who have progressed on or are unsuitable for standard therapies. The drug is administered as an injection. While specific details regarding its molecular target have not been widely publicized in clinical trial registries, it belongs to the portfolio of a company specializing in recombinant protein and monoclonal antibody technologies.

Beyond the preview

Go deeper on MG2512.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG2512.

Explore the full profile